Cell line · CVCL_1662
RMG-I
Cancer cell line, Homo sapiens. Ovarian clear cell adenocarcinoma. 43 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. RMG-I. Cell lines, record CVCL_1662. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1662
On this page
Cell line
As Cellosaurus gives it.
- Name
- RMG-I
- Accession
- CVCL_1662
- RRID
- RRID:CVCL_1662
- Synonyms
- RMGI, RMG1, RMG-1
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 34Y
- Category
- Cancer cell line
- Diseases
- Ovarian clear cell adenocarcinoma (NCIt C40078); Clear cell adenocarcinoma of the ovary (ORDO Orphanet_398971)
- Derived from
- Ascites (metastatic)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers43
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the CHD3 chromatin remodeler exploits a synthetic lethal vulnerability in dual SMARCA4/SMARCA2-deficient cancers via derepression of PARD3B. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BMAL2 is a druggable target for ovarian clear cell carcinoma (OCCC). | EMBO Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Metabolome analysis identified exogenous cholesterol within lipid rafts that activate the Akt/mTOR signaling pathway in epithelial ovarian cancer. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of glycolysis and stimulation of mitochondrial biogenesis lead to increased ROS levels and cell death in HNF-1ß positive clear cell carcinoma. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Characterization of a fluorescence imaging probe that exploits metabolic dependency of ovarian clear cell carcinoma. | Sci Rep | 2023 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 43
See all 43 papersRelatives2
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | RMG-I-C | CVCL_IS64 | Cell lines | |
| Derived from it | RMG-I-H | CVCL_IS65 | Cell lines |
Cell banks3
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| JCRB | FDSC0027 | Discontinued | Cellosaurus |
| JCRB | IFO50315 | JCRB | |
| JCRB | JCRB0172 | JCRB |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1662
GET https://conductscience.org/api/cell-lines/v1/CVCL_1662/papers?page=2